Multiple Myeloma and Other Plasma Cell Neoplasms

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Hematology, Oncology
Cover of the book Multiple Myeloma and Other Plasma Cell Neoplasms by , Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9783319255866
Publisher: Springer International Publishing Publication: February 16, 2018
Imprint: Springer Language: English
Author:
ISBN: 9783319255866
Publisher: Springer International Publishing
Publication: February 16, 2018
Imprint: Springer
Language: English

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find *Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management. *

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

This book is a comprehensive source of up-to-date information on plasma cell neoplasms. Key features include the provision of new criteria for the diagnosis of symptomatic multiple myeloma requiring treatment and the description of novel therapies for myeloma and other plasma cell neoplasms that have only very recently been licensed by the U.S. Food and Drug Administration. Examples include lenalidomide as first-line therapy, panobinostat in combination with bortezomib plus dexamethasone for relapsed/refractory myeloma, ibrutinib for Waldenström’s macroglobulinemia, and new therapeutic regimens for systemic amyloidosis and POEMS syndrome. Information is also provided on drug combinations that have shown encouraging results and are very near to approval. Other important aspects covered in the book are the role of different imaging modalities in workup and the significance of newly acquired data relating to prognosis and minimal residual disease. Readers will find *Multiple Myeloma and Other Plasma Cell Neoplasms to be a rich source of knowledge that will be invaluable in improving patient management. *

More books from Springer International Publishing

Cover of the book Gems in the Early Modern World by
Cover of the book Hermeneutic Realism by
Cover of the book Progestogens in Obstetrics and Gynecology by
Cover of the book Phenomenology and Intercultural Understanding by
Cover of the book Creativity and Innovation by
Cover of the book Human Interface and the Management of Information. Information in Intelligent Systems by
Cover of the book International Conference on Oriental Thinking and Fuzzy Logic by
Cover of the book Social Robots from a Human Perspective by
Cover of the book Machine Learning in Medicine - Cookbook Two by
Cover of the book Statistical Atlases and Computational Models of the Heart. Imaging and Modelling Challenges by
Cover of the book Cardiovascular Safety in Drug Development and Therapeutic Use by
Cover of the book Multiscale Modeling of Complex Molecular Structure and Dynamics with MBN Explorer by
Cover of the book Queering Agatha Christie by
Cover of the book Finding One’s Way Through Wittgenstein’s Philosophical Investigations by
Cover of the book Synthesis and Reactivity of Donor-Acceptor Substituted Aminocyclopropanes and Aminocyclobutanes by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy